XML 108 R96.htm IDEA: XBRL DOCUMENT v3.25.2
Segment Information - Schedule of Segment Results (Details) - EUR (€)
€ in Millions
 6 Months Ended
Jun. 30, 2025
Jun. 30, 2024
Disclosure of operating segments [Line Items]    
Net sales € 19,889 € 18,360 [1],[2]
Other revenues 1,452 1,529 [2],[3]
Cost of sales (5,881) (5,966) [2]
Research and development expenses (3,717) (3,335) [2]
Selling and general expenses (4,506) (4,303) [2]
Net income attributable to non-controlling interests 25 17 [2]
Reportable segments [member]    
Disclosure of operating segments [Line Items]    
Net sales 19,889 18,360 [4]
Other revenues 1,452 1,529 [4]
Cost of sales (5,881) (5,959) [4]
Research and development expenses (3,717) (3,335) [4]
Selling and general expenses (4,506) (4,303) [4]
Miscellaneous Other Operating Income (Expenses) (1,943) (1,414) [4]
Share of profit (loss) of associates and joint ventures accounted for using equity method 77 66 [4]
Net income attributable to non-controlling interests (8) (6) [4]
Business Operating Income 5,363 4,938 [4]
Biopharma Segment [Member]    
Disclosure of operating segments [Line Items]    
Net sales 19,889 18,360 [1],[4]
Other revenues 1,246 1,352 [3],[4]
Cost of sales (5,753) (5,849) [4]
Research and development expenses (3,716) (3,334) [4]
Selling and general expenses (4,447) (4,247) [4]
Miscellaneous Other Operating Income (Expenses) (1,941) (1,426) [4]
Share of profit (loss) of associates and joint ventures accounted for using equity method 77 66 [4]
Net income attributable to non-controlling interests (8) (6) [4]
Business Operating Income 5,347 4,916 [4]
Other    
Disclosure of operating segments [Line Items]    
Net sales [5] [4]
Other revenues 206 [5] 177 [4]
Cost of sales (128) [5] (110) [4]
Research and development expenses (1) [5] (1) [4]
Selling and general expenses (59) [5] (56) [4]
Miscellaneous Other Operating Income (Expenses) (2) [5] 12 [4]
Share of profit (loss) of associates and joint ventures accounted for using equity method 0 [5] 0 [4]
Net income attributable to non-controlling interests 0 [5] 0 [4]
Business Operating Income € 16 [5] € 22 [4]
[1] Figures for 2024 comparative period have been re-presented on a consistent basis to reflect the classification of Opella as a discontinued operation.
[2] Figures for the 2024 comparative period have been re-presented on a consistent basis to reflect the classification of Opella as a discontinued operation.
[3]
(a)    Figures for the 2024 comparative period have been re-presented on a consistent basis to reflect the classification of Opella as a discontinued operation.
[4] Figures for the 2024 comparative period have been re-presented on a consistent basis to reflect the classification of Opella as a discontinued operation.
[5]